ClinicalTrials.gg
CompletedNCT05878067Updated Oct 15, 2024Results posted

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

A Phase 3 interventional study of ABBV-444 in Dry Eye Syndrome, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.

Enrollment
32nd of 40
40 · median 80
Started
2023
the only one that year
Phase 3
12 of 48
none open now
Registered
44th of 48
by date

Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 32nd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2023, is one of 12 in phase 3, and was the 44th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Dry Eye Syndromes by AbbVie, or all of them as a file.
02

Study summary

Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants.

ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day, open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around 40 participants will be enrolled in 1 site in the United States.

Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

Keywords

  • Dry Eye Syndrome
  • ABBV-444
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had used artificial tears for dry eyes within the past year
  • OSDI score of ≥ 18 and ≤ 65 (based upon a 0 to 100 scale) at Screening and Baseline Visits Three consecutive tear breakup time (TBUT) tests ≤ 10 seconds in at least 1 eye at Day -7 (screening)
  • Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that was related to dry eye in at least 1 eye at both at Screening and Baseline Visits

Exclusion criteria

Exclusion Criteria:

  • Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)
  • Known allergy or sensitivity to the study products or their components
  • Schirmer Test (with anesthesia) ≤ 2 mm in either eye at Screening Visit
  • Participant anticipated contact lens wear during the study, or the participant had worn contact lenses in the last 3 months prior to Screening Visit
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ABBV-444

    Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.

    Drug: ABBV-444

Interventions

  • DrugABBV-444

    Lubricant Eye drops

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score

    The OSDI is a 12-question survey for participants to document their dry eye disease symptoms. The OSDI consists of a 5-point scale ranging from 0 (none of the time) to 4 (all of the time), with higher scores representing greater disability. The scores from the 12 questions are totaled and converted to an overall score ranging from 0 (no disability) to 100 (complete disability). A negative number change from baseline represents an improvement.

    Time frame: Baseline to Day 30

Secondary outcomes

  1. Patient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale)

    The PEDE Survey is a 13-item questionnaire that evaluates the short- and long-term subjective experience in comfort and vision as well as tolerability, using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). On Day 30, participants were asked to retrospectively recall their experiences after 5 minutes, 30 minutes, 24 hours, and 5 days of when they administered the eye drops

    Time frame: Day 30

  2. Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444

    The Current Symptom Survey is a 5-item questionnaire where the participants rate their ocular symptoms at the present moment using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). Surveys were completed 5 minutes following the first administration of study eye drops. A negative number change from baseline represents an improvement.

    Time frame: Baseline (T0) to 5 minutes (T5)

07

Results

Posted Oct 15, 2024

Participant flow

A total of 40 participants were enrolled and included in the intent-to-treat (ITT) population. The per-protocol (PP) population included 34 participants after excluding 4 participants who were deemed protocol deviations and 2 participants who discontinued the study. The per-protocol population was used for all efficacy measures.

Participant flow — Overall Study
MilestoneABBV-444
Started40
Completed38
Not completed2
Withdrew: Lost to follow-up2

Outcome measures

PrimaryChange From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score

The OSDI is a 12-question survey for participants to document their dry eye disease symptoms. The OSDI consists of a 5-point scale ranging from 0 (none of the time) to 4 (all of the time), with higher scores representing greater disability. The scores from the 12 questions are totaled and converted to an overall score ranging from 0 (no disability) to 100 (complete disability). A negative number change from baseline represents an improvement.

Time frame:
Baseline to Day 30
Reported as:
Mean · score on a scale
Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score
score on a scaleABBV-444
Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score-6.8 ± 15.0
SecondaryPatient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale)

The PEDE Survey is a 13-item questionnaire that evaluates the short- and long-term subjective experience in comfort and vision as well as tolerability, using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). On Day 30, participants were asked to retrospectively recall their experiences after 5 minutes, 30 minutes, 24 hours, and 5 days of when they administered the eye drops

Time frame:
Day 30
Reported as:
Mean · score on a scale
Patient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale)
score on a scaleABBV-444
The study eye drops do not cause stinging or burning in my eyes (5 minutes)76.4 ± 36.7
Study eye drops provided immediate relief of my eye dryness when putting in my eyes (5 minutes)77.1 ± 27.9
Study eye drops immediately soothed my eye dryness when putting in my eyes (5 minutes)81.3 ± 25.3
Did not experience much blurry/fluctuating vision after putting study eye drops in my eyes (5 mins)77.5 ± 30.4
Study eye drops provided immediate comfort to my eye dryness when putting in my eyes (5 minutes)84.1 ± 21.1
The study eye drops are very soothing for my eye dryness (30 minutes)82.0 ± 25.6
The study eye drops did not feel sticky (30 minutes)78.6 ± 30.8
The study eye drops continued to provide relief of my eye discomfort (30 minutes)84.6 ± 20.7
The study eye drops continued to provide comfort to my eye dryness (30 minutes)85.7 ± 21.0
The study eye drops provided relief of my eye dryness day and night (24 hours)84.4 ± 20.0
The study eye drops provided comfort to my eye dryness day and night (24 hours)84.5 ± 21.5
The study eye drops provided lasting relief of my eye dryness (5 days)83.8 ± 23.2
The study eye drops have provided relief during conditions that lead to eye dryness (5 days)82.0 ± 22.6
SecondaryChange From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444

The Current Symptom Survey is a 5-item questionnaire where the participants rate their ocular symptoms at the present moment using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). Surveys were completed 5 minutes following the first administration of study eye drops. A negative number change from baseline represents an improvement.

Time frame:
Baseline (T0) to 5 minutes (T5)
Reported as:
Mean · score on a scale
Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444
score on a scaleABBV-444
Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444-10.1 ± 10.6

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to end of study. Safety events (per protocol) were collected from enrollment through the 30 day treatment period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABBV-4440/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

ITT population: Includes all enrolled participants who received at least one dose of study drug

Age, Continuous
Age, Continuous(years)ABBV-444
Mean37.7 ± 15.8
Sex: Female, Male
Sex: Female, Male(Participants)ABBV-444
Female24
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ABBV-444
Hispanic or Latino38
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABBV-444
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White38
More than one race0
Unknown or Not Reported1
08

Study locations

1 site
  • Canyon City Eyecare /ID# 253652
    Azusa, California 91702, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2023, 3 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
May 26, 2023
StartActual
Jun 27, 2023
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05878067
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jun 27, 2023
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion